Schwarz LJ et al. |
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. |
2017 |
J. Natl. Cancer Inst. |
pmid:29059433
|
Chen SC et al. |
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). |
2017 |
Cancer Chemother. Pharmacol. |
pmid:29043411
|
Li C et al. |
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. |
2017 |
Cancer Chemother. Pharmacol. |
pmid:29022084
|
La Monica S et al. |
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. |
2017 |
J. Exp. Clin. Cancer Res. |
pmid:29202823
|
Fabi A et al. |
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? |
2017 |
Future Oncol |
pmid:29182361
|
Zhang J et al. |
Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis. |
2017 |
Drug Des Devel Ther |
pmid:29180848
|
Diaby V et al. |
Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. |
2017 |
Breast Cancer Res. Treat. |
pmid:28840424
|
Andreev J et al. |
Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. |
2017 |
Mol. Cancer Ther. |
pmid:28108597
|
Schönfeld K et al. |
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. |
2017 |
J Hematol Oncol |
pmid:28077160
|
Moore KN et al. |
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. |
2017 |
J. Clin. Oncol. |
pmid:28029313
|
Geraud A et al. |
Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer. |
2017 |
J. Neurooncol. |
pmid:27995546
|
Yap LW et al. |
Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis. |
2017 |
Fetal Pediatr Pathol |
pmid:27935326
|
Zhao M et al. |
Effects of the Methylmalonyl-CoA Metabolic Pathway on Ansamitocin Production in Actinosynnema pretiosum. |
2017 |
Appl. Biochem. Biotechnol. |
pmid:27787765
|
Baldassarre T et al. |
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers. |
2017 |
Breast Cancer Res. |
pmid:28974266
|
Ning X et al. |
Identification and Engineering of Post-PKS Modification Bottlenecks for Ansamitocin P-3 Titer Improvement in Actinosynnema pretiosum subsp. pretiosum ATCC 31280. |
2017 |
Biotechnol J |
pmid:28881098
|
van Boxtel W et al. |
Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma. |
2017 |
Oral Oncol. |
pmid:28673692
|
Ait-Oudhia S et al. |
A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates. |
2017 |
AAPS J |
pmid:28646408
|
Carvajal-Hausdorf DE et al. |
Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. |
2017 |
Gynecol. Oncol. |
pmid:28196634
|
Perez EA et al. |
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. |
2017 |
J. Clin. Oncol. |
pmid:28056202
|
Parikh A et al. |
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. |
2017 |
J Natl Compr Canc Netw |
pmid:28040715
|